Global RNAI Technology Market - 2020-2027
発行: DataM Intelligence
RNA interference is the process of the protein translation is prevented through the selective degradation of its encoded mRNA. It eliminates the unwanted foreign genes as a defense against viruses. It inhibits the gene expression or translation, by neutralizing the targeted mRNA molecules. The global RNAI Technology market valued USD XX million in 2019 and it is expected to grow at a CAGR of XX% to reach USD XX million by 2020-2027.
The market is driven by the increasing demand for the RNAi therapeutics due to the increasing usage of the RNAi therapeutics in the molecular diagnostics. There is increasing adoption of the RNAi therapeutics for the cancer diagnosis and treatment. These therapeutics are useful in improving the synthetic delivery carriers and chemical modifications to RNA. RNAi therapeutics exhibit several growth inhibition, antiangiogentic, chemosensitizing, apoptosis inducing, and antioncogenic properties. RNAi techniques are the essential for the identification of altered cellular molecules and metabolites.
There is increase in the approval for the RNAi therapeutics. For instance, in November 2019, Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company had received the approval for the Givlaari (givosiran) injection for subcutaneous use for the treatment of adults with acute hepatic porphyria (AHP). Givlaari is the RNAi therapeutic that is effective in reducing the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or IV hemin administration at home.
In August 2018, Alnylam Pharmaceuticals, Inc. had received the approval for the Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. It is the first FDA approval of a new class of drugs called small interfering ribonucleic acid (siRNA) treatment. Onpattro acts by silencing a portion of RNA involved in causing the disease.
There is increase in the research and development (R&D) for the development of the RNAi therapeutics. For instance, in March 2020, OliX Pharmaceuticals, Inc., had leverage previous preclinical research for developing siRNA therapeutics for the treatment of the respiratory illnesses to investigate a path forward for developing a COVID-19 therapy. OliX Pharmaceuticals would plan the further investigate for an advanced pre-clinical therapeutic candidate that could protect against COVID-19. The company's siRNAs have demonstrated an efficient knockdown of the viral RNA sequences through in vitro assay.
The global RNAI Technology market is segmented based on the application as the cancer, infectious diseases, ophthalmic diseases, genetic diseases, and other diseases. The cancer segment accounts for the highest market share of XX% in 2019. There is growing usage of the RNAI Technology for the development of the personalized medicine and molecular diagnostics for the diagnosis and treatment of the cancer. RNA interference (RNAi) can target the cancer-related genes. There is increasing development of the gene products involved in tumorigenesis using the RNAi based therapy.
There is growing development of the small interfering RNA (siRNA) tolerant to nucleases and non-viral vectors, such as cationic liposomes and nanoparticles for facilitating the use of RNAi-based therapeutics for the cancer treatment. The next generation of RNAi-based therapies for cancer are based on personalized treatments. The RNAi therapeutics act by disrupting the signaling pathways. RNAi acts by inhibiting the tumor growth by modifying the ratio of tumor/ T-cell activation, induction of apoptosis to increase antigen presenting, and reducing local and systemic immunosuppression associated with immunotherapy.
By region, the global RNAI technology market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global RNAI technology market and expected to grow at the highest CAGR during the forecasted period due to the higher adoption of RNAi high-throughput screening for the development of RNAi therapeutic, identification of therapeutic targets, gene regulation novel signaling pathway, and cancer gene screening. There is growing research and development activities for the RNAI therapeutics for the treatment of the various diseases such as cancer, infectious diseases, ophthalmic diseases, genetic diseases, and other diseases. Several public and private players are raising the investment for the development of the RNAI therapeutics. There is higher adoption of the RNAi technology for identifying and targeting the undruggable carcinogenic molecules. Several companies are developing the RNAi-based targeted cancer therapies using advanced lipid and polymer-based nanocarriers as a delivery platform.
Asia Pacific is expected to have the positive market growth due to the increase in the number of the market players developing the RNAI therapeutics. There is growing usage of the RNAi technologies for drug discovery, therapeutics, and medical research. The increasing number of the people with cancer, infectious diseases, ophthalmic diseases, genetic diseases, and other diseases shall stimulate the market growth.
The global RNAI Technology market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Alnylam Pharmaceuticals, Arbutus Biopharma Corp., Arrowhead, Bio-Rad Laboratories Inc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Qiagen NV, and Thermo Fisher Scientific Inc. are the leading market players with significant market share.
The major players are using collaborations, acquisitions, mergers, market expansion, capacity utilization, and licensing strategies for holding their position in the market. For instance, in April 2020, Blackstone Medical Inc. had entered into the collaboration with the Alnylam Pharmaceuticals Inc., the leading RNAi therapeutics company. Under the terms of the agreement, Blackstone would provide up to $2 billion to support Alnylam's advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases. Inclisiran is a twice-a-year, subcutaneously injected RNAi therapeutic that had demonstrated to reduce the low- density lipoprotein (LDL) or "bad" cholesterol with an acceptable safety profile.
In January 2020, Novartis had acquired The Medicines Company, focuses on developing the RNA drug i.e., inclisiran for the treatment of cardiovascular disease and renal impairment. Inclisiran is an RNA drug that blocks the production of a protein called PCSK9 in a process called RNA interference, or RNAi. It acts by inhibiting the production of this protein protects against cardiovascular disease. The drug had met the primary endpoint in three phase III trials for the treatment of cardiovascular disease.
In October 2017, Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company had entered into the collaboration with the Vir Biotechnology, a company dedicated to transforming the care of people with serious infectious diseases, for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus (HBV) infection. Under the terms of the agreement, the companies would advance Alnylam's HBV program and also initiate a research collaboration for the development and advancement of up to four additional RNAi therapeutic programs for the treatment of other infectious diseases with high unmet needs.
In January 2014, Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company had acquired the Merck's wholly owned subsidiary Sirna Therapeutics, Inc comprising the intellectual property and RNAi assets including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies. This acquisition would help the company to complement and extend the progress and continued focus on RNAi therapeutics, including siRNA-conjugate technologies. Under the terms of the agreement, Alnylam would pay Merck an upfront payment of $175 million in cash and equity for acquiring the stock of Sirna Therapeutics. Merck would be eligible to receive up to $105 million in developmental and sales milestone payments per product, along with the single-digit royalties, associated with the progress of certain pre-clinical candidates discovered by Merck.
Several companies are raising the investment for the development of the RNAi products. For instance, in April 2020, Alnylam Pharmaceuticals, a pioneer in the field of RNA interference (RNAi) medicines had entered into the collaboration with the Blackstone. Under the terms of the agreement, Blackstone would provide up to $2 billion to support Alnylam's advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases.